The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.
Current hormonal therapies have benefited millions of patients with breast cancer. Their success, however, is often temporary and limited to a subset of patients whose tumors express estrogen receptor alpha (ER). The therapies are entirely ineffective in ER-negative disease. Recent studies suggest that there are many biological pathways and alterations involved in determining whether ER is expressed and how it is regulated during breast cancer evolution. Improving hormonal therapies, in addition to perfecting current strategies, will also target these newly discovered pathways and alterations, and others yet to be found. The present commentary will briefly highlight a few important observations and unanswered questions regarding ER status and growth regulation during breast cancer evolution, which hopefully will help to stimulate new thinking and progress in this important area of medial research.
Allred
D Craig
DC
Breast Center/Department of Pathology, Baylor College of Medicine, Houston, Texas, USA. dcallred@breastcenter.tmc.edu
Brown
Powel
P
Medina
Daniel
D
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D048708:Cell Growth Processes / Q000502:physiology; D047628:Estrogen Receptor alpha / Q000096:biosynthesis*; D006801:Humans
D018931:Antineoplastic Agents, Hormonal; D047628:Estrogen Receptor alpha